Q3 Earnings Estimate for BDTX Issued By HC Wainwright

Key Points

• HC Wainwright analysts predict Black Diamond Therapeutics will report earnings of ($0.24) per share for Q3 2025, maintaining a "Buy" rating with a price target of $10.00.
• The company's recent earnings report showed a loss of ($0.19) per share, which exceeded the consensus estimate of ($0.25) by $0.06.
• Institutional investors collectively own 95.47% of Black Diamond Therapeutics, indicating a strong interest from financial institutions.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at $0.33 EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS and Q4 2026 earnings at ($0.27) EPS.

A number of other equities research analysts have also recently commented on the company. Zacks Research raised Black Diamond Therapeutics to a "strong-buy" rating in a research note on Monday, August 11th. Wall Street Zen cut Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Raymond James Financial upgraded Black Diamond Therapeutics to an "outperform" rating and set a $11.00 target price on the stock in a report on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $12.40.

Black Diamond Therapeutics Stock Down 3.8%

Shares of Black Diamond Therapeutics stock traded down $0.1050 during trading on Thursday, reaching $2.6450. 375,927 shares of the company were exchanged, compared to its average volume of 1,983,603. Black Diamond Therapeutics has a twelve month low of $1.20 and a twelve month high of $6.75. The business has a 50-day moving average price of $2.66 and a 200-day moving average price of $2.15. The firm has a market capitalization of $150.61 million, a price-to-earnings ratio of 11.50 and a beta of 2.87.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.06.

Institutional Trading of Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BDTX. R Squared Ltd bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $25,000. Cerity Partners LLC bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $26,000. Hudson Bay Capital Management LP bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $26,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $28,000. Finally, American Century Companies Inc. bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 95.47% of the company's stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.